The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary ...

Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Detailed price information for Day One Biopharmaceuticals Inc (DAWN-Q) from The Globe and Mail including charting and trades.

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

GATC brought together a broad coalition of researchers and executives in cell and gene therapy, gene editing, drug discovery and AI as well as patients and advocates.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?

Ovid Therapeutics announced it will name its president and chief operating officer Meg Alexander as its new CEO – replacing Jeremy Levin, effective January 1, 2026. She will also join the board of ...